Skip to main content

Mutation-tracking blood test offers early detection of breast cancer relapse

Mutation-tracking’ blood test could predict breast cancer relapse
Scientists from the UK’s Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust have created a DNA-based blood test that can determine whether a breast cancer patient is at risk for relapse. The test can detect a recurrence several months before any other physical signs are evident, potentially making it useful as an early warning tool for these who have completed breast cancer treatment.

The blood test is engineered to detect minute quantities of tumor DNA in a patient’s bloodstream. This DNA emanates from the original tumor and is often left behind following cancer treatment. Each patient’s cancer cells are collected and the test is tailor-made to detect these unique tumor cells. These leftover cancer cells are critical to identify as they may eventually form new tumors and lead to a recurrence of breast and other cancers in patients.

blood testIn a study published in Science Translational Medicine, researchers collected blood samples from 55 women who were diagnosed with for early-stage breast cancer and successfully completed treatment for the disease. The research shows that patients with a detectable level of circulating tumor DNA were 12 times more likely to experience a relapse than those who tested negative for the cancer-originating DNA. The blood test also was able to predict a recurrence up to eight months before any physical signs of the cancer appeared.

The method is beneficial to physicians and patients alike as it utilizes a routine, non-invasive blood test that can safely repeated based on an individual patient’s treatment plan. It also avoids more expensive and invasive procedures such as mammograms, CAT scans, and biopsies. Given these advantages, the test will potentially make it easy for physicians to monitor breast cancer patients following treatment and provide early intervention if the risk of recurrence begins to climb.

Because of its early detection capability, researchers hope this blood test will “make a real difference to breast cancer patients,” but it is still in the early stage of development. Before it can be considered as an important diagnostic test, researchers need to expand their trials so they examine more closely whether the early detection provided by the test will lead to a positive outcome for patients.

Editors' Recommendations

Kelly Hodgkins
Kelly's been writing online for ten years, working at Gizmodo, TUAW, and BGR among others. Living near the White Mountains of…
This AI cloned my voice using just three minutes of audio
acapela group voice cloning ad

There's a scene in Mission Impossible 3 that you might recall. In it, our hero Ethan Hunt (Tom Cruise) tackles the movie's villain, holds him at gunpoint, and forces him to read a bizarre series of sentences aloud.

"The pleasure of Busby's company is what I most enjoy," he reluctantly reads. "He put a tack on Miss Yancy's chair, and she called him a horrible boy. At the end of the month, he was flinging two kittens across the width of the room ..."

Read more
Digital Trends’ Top Tech of CES 2023 Awards
Best of CES 2023 Awards Our Top Tech from the Show Feature

Let there be no doubt: CES isn’t just alive in 2023; it’s thriving. Take one glance at the taxi gridlock outside the Las Vegas Convention Center and it’s evident that two quiet COVID years didn’t kill the world’s desire for an overcrowded in-person tech extravaganza -- they just built up a ravenous demand.

From VR to AI, eVTOLs and QD-OLED, the acronyms were flying and fresh technologies populated every corner of the show floor, and even the parking lot. So naturally, we poked, prodded, and tried on everything we could. They weren’t all revolutionary. But they didn’t have to be. We’ve watched enough waves of “game-changing” technologies that never quite arrive to know that sometimes it’s the little tweaks that really count.

Read more
Digital Trends’ Tech For Change CES 2023 Awards
Digital Trends CES 2023 Tech For Change Award Winners Feature

CES is more than just a neon-drenched show-and-tell session for the world’s biggest tech manufacturers. More and more, it’s also a place where companies showcase innovations that could truly make the world a better place — and at CES 2023, this type of tech was on full display. We saw everything from accessibility-minded PS5 controllers to pedal-powered smart desks. But of all the amazing innovations on display this year, these three impressed us the most:

Samsung's Relumino Mode
Across the globe, roughly 300 million people suffer from moderate to severe vision loss, and generally speaking, most TVs don’t take that into account. So in an effort to make television more accessible and enjoyable for those millions of people suffering from impaired vision, Samsung is adding a new picture mode to many of its new TVs.
[CES 2023] Relumino Mode: Innovation for every need | Samsung
Relumino Mode, as it’s called, works by adding a bunch of different visual filters to the picture simultaneously. Outlines of people and objects on screen are highlighted, the contrast and brightness of the overall picture are cranked up, and extra sharpness is applied to everything. The resulting video would likely look strange to people with normal vision, but for folks with low vision, it should look clearer and closer to "normal" than it otherwise would.
Excitingly, since Relumino Mode is ultimately just a clever software trick, this technology could theoretically be pushed out via a software update and installed on millions of existing Samsung TVs -- not just new and recently purchased ones.

Read more